Healio8h
Researchers define quality-of-life domains for chronic graft-versus-host disease
Researchers found a direct relationship between cutaneous chronic graft-versus-host disease and health-related quality-of-life domains that are not currently included as measurements in clinical ...
Pharm Exec6d
FDA Approves Incyte and Syndax’s Niktimvo for Chronic Graft-Versus-Host Disease in 9 and 22 mg Vial Sizes
Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...
Medindia3d
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
About THANK-uCAR® THANK (Target to Hinder the Attack of NK cells)-uCAR® is CARsgen's proprietary technology to generate allogeneic CAR-T cells with improved expansion and persis ...
Oncology Nurse Advisor13h
Mesenchymal Stromal Cell Therapy Ryoncil Gets FDA Approval
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Monthly Prescribing Reference1d
FDA Approves New Vial Sizes for GVHD Treatment Niktimvo
The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
pharmaphorum3d
Mesoblast finally pushes GvHD cell therapy over finish line
At its third attempt, Mesoblast has secured FDA approval for Ryoncil as a treatment for children with graft-versus-host disease ... steroid-refractory acute GVHD in paediatric patients aged ...
Targeted Oncology6d
FDA Approves Axatilimab for Chronic GVHD in New Vial Sizes
Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...
pharmaphorum2d
Mesoblast poised to file cell therapy for GVHD in US
Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA. The ‘rolling ...
Pharmabiz5d
US FDA approves Incyte and Syndax’s Niktimvo 9 mg & 22 mg vial sizes to treat chronic graft-versus-host disease
US FDA approves Incyte and Syndax’s Niktimvo 9 mg & 22 mg vial sizes to treat chronic graft-versus-host disease: Wilmington, Delaware Friday, January 17, 2025, 13:30 Hrs [IST] I ...
Medindia6d
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.
Future Market Insights6d
Global Allogeneic T-cell Therapies Market Poised for Significant Growth, Projected to Reach USD 3.08 Billion by 2033 register a CAGR of 9.8%
According to a recent report from Future Market Insights, the global allogeneic T-cell therapies market was valued at USD 1.1 ...